# A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind

Source: https://onco.cc/trials/nct06577025/  
OnCo record `nct06577025` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ciltacabtagene autoleucel, Talquetamab, Daratumumab in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.

## Summary

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma is a phase 2 interventional study registered as NCT06577025 by Janssen Research & Development, LLC, with 43 participants enrolled, started 2024-08-20 and due to reach its primary completion in 2030-09-02. Interventions recorded: Cilta-cel, Talquetamab, Daratumumab, Teclistamab, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06577025
- Phase: 2
- Setting: A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 43

## Sources

- ClinicalTrials.gov NCT06577025: https://clinicaltrials.gov/study/NCT06577025

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Bortezomib](https://onco.cc/drugs/bortezomib/), [Ciltacabtagene autoleucel](https://onco.cc/drugs/ciltacabtagene-autoleucel/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Talquetamab](https://onco.cc/drugs/talquetamab/), [Teclistamab](https://onco.cc/drugs/teclistamab/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct06577025.json